Clinical trial
A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients
NCT00664703 is registered in ClinicalTrials.gov with Yaupon Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients
- Lead sponsor
- Yaupon Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2008
- Completion date
- January 31, 2010
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.